“Hinge Health's stock advanced following an earnings beat, an upward revision to full-year guidance, and accelerating client bookings. The company also introduced new long-term growth targets and achieved a favorable market reception for its new migraine offering, demonstrating commercial strength despite broad weakness in digital health.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.